DAVOLINK Finalizes Third-Party Allotment Capital Increase: 944,870 New Shares at 1,020 Won, Small-Scale Operational Funding with Modest Dilution
The company finalized the terms of its capital increase through an amendment to the initial decision filed on January 20, 2026.
The number of new shares was increased from 787,400 to 944,870 with an issue price of 1,020 won, representing a 17.2% discount to the reference price.
Proceeds of approximately 964 million won will be used for operational expenses, with no linkage to specific growth projects or facility investments, limiting positive stock price impact.
The dilution ratio stands at about 1.82%, relatively minor, but the counterparty Medichal Rich is a corporation with only 1 million won in capital and plans to fund the subscription through borrowing, raising credit risk concerns.
The reference price was set at 869.74 won, the weighted average price from the third to fifth trading days before the subscription date, with payment on July 13 and listing scheduled for August 4.
[AI Summary]This amendment finalizes the capital increase terms, resulting in a slightly higher dilution for existing shareholders due to increased share count and a larger discount. The funds are allocated for operating expenses without growth catalysts, and the weak financial standing of the third-party allotment adds uncertainty.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)